Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up? Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate ...

Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up​Enrollment for registrational Phase ...

Dr. Shukla continued, “We are encouraged by the potential of efzofitimod to improve the lives of those living with sarcoidosis, and we are incredibly grateful to the patients, investigators, patient ...